Sandbox bcce8
From Proteopedia
(Difference between revisions)
Line 1: | Line 1: | ||
==β-Glucuronidase== | ==β-Glucuronidase== | ||
<StructureSection load='3hn3' size='340' side='right' caption='Caption for this structure' scene=''> | <StructureSection load='3hn3' size='340' side='right' caption='Caption for this structure' scene=''> | ||
- | This tutorial illustrates the quaternary structures of the human and E. coli &beta-glucuronidase enzyme. | + | This tutorial illustrates the quaternary structures of the human and E. coli β-glucuronidase enzyme. |
== Function == | == Function == | ||
- | &beta-glucuronidase is a ubiquitous enzyme that catalyzes the hydrolysis of a glucuronide moiety from a variety of substrates. This enzyme is present throughout biological systems, including bacteria up through humans. | + | β-glucuronidase is a ubiquitous enzyme that catalyzes the hydrolysis of a glucuronide moiety from a variety of substrates. This enzyme is present throughout biological systems, including bacteria up through humans. |
== Relevance == | == Relevance == | ||
Deficiencies in the human form of &beta-glucuronidase is associated with a disease known as Sly Syndrome (AKA Mucopolysaccharidosis VII -- MPS VII). This disease is characterized by mental retardation, short stature, macrocephaly, and enlarged joints. As is commonly seen with genetic disorders, patients with this disease present a spectrum of symptom severity, but the disease is always ultimately fatal. | Deficiencies in the human form of &beta-glucuronidase is associated with a disease known as Sly Syndrome (AKA Mucopolysaccharidosis VII -- MPS VII). This disease is characterized by mental retardation, short stature, macrocephaly, and enlarged joints. As is commonly seen with genetic disorders, patients with this disease present a spectrum of symptom severity, but the disease is always ultimately fatal. | ||
- | The E. coli form of &beta-glucuronidase is associated with the side effects seen with administration of the cancer chemotherapy drug CPT-11. This drug gets converted to SN38, a topoisomerase inhibitor, by the liver. The body adds a glucuronide group to this molecule (now SN38-G) to mark it for elimination, which partially occurs through the intestine. Once in the intestine, bacterial | + | The E. coli form of β-glucuronidase is associated with the side effects seen with administration of the cancer chemotherapy drug CPT-11. This drug gets converted to SN38, a topoisomerase inhibitor, by the liver. The body adds a glucuronide group to this molecule (now SN38-G) to mark it for elimination, which partially occurs through the intestine. Once in the intestine, bacterial β-glucuronidase cleaves the glucuronide from the SN38-G, releasing the SN38 into the intestinal lumen. The released SN38 prevents cell division, compromising the epithelial lining of the intestines, a painful and dangerous side-effect of CPT-11 administration. |
- | Selective inhibition of bacterial &beta-glucuronidase is desired to alleviate this side-effect of CPT-11 treatment, hopefully without inhibiting the human form of the enzyme. | + | Selective inhibition of bacterial β-glucuronidase is desired to alleviate this side-effect of CPT-11 treatment, hopefully without inhibiting the human form of the enzyme. |
Revision as of 14:39, 6 August 2014
β-Glucuronidase
|